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The use of vaccination against the influenza virus remains the most effective method of
mitigating the significant morbidity and mortality caused by this virus. Antibodies elicited
by currently licensed influenza vaccines are predominantly hemagglutination-inhibition (HI)-
competent antibodies that target the globular head of hemagglutinin (HA) thus inhibiting
influenza virus entry into target cells. These antibodies predominantly confer homosub-
typic/strain specific protection and only rarely confer heterosubtypic protection. However,
recent academia or pharma-led R&D toward the production of a “universal vaccine” has
centered on the elicitation of antibodies directed against the stalk of the influenza HA
that has been shown to confer broad protection across a range of different subtypes (H1–
H16). The accurate and sensitive measurement of antibody responses elicited by these
“next-generation” influenza vaccines is, however, hampered by the lack of sensitivity of
the traditional influenza serological assays HI, single radial hemolysis, and microneutraliza-
tion. Assays utilizing pseudotypes, chimeric viruses bearing influenza glycoproteins, have
been shown to be highly efficient for the measurement of homosubtypic and heterosub-
typic broadly neutralizing antibodies, making them ideal serological tools for the study of
cross-protective responses against multiple influenza subtypes with pandemic potential.
In this review, we will analyze and compare literature involving the production of influenza
pseudotypes with particular emphasis on their use in serum antibody neutralization assays.
This will enable us to establish the parameters required for optimization and propose a con-
sensus protocol to be employed for the further deployment of these assays in influenza
vaccine immunogenicity studies.
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INFLUENZA PSEUDOTYPES
Influenza is a respiratory syndrome caused by three of six gen-
era in the orthomyxoviridae family, influenza A, B, and C. A
putative fourth genus (influenza D) has recently been charac-
terized and proposed (1). Influenza A is the most widespread,
its various subtypes are classified according to their antigeni-
cally variable surface glycoproteins: hemagglutinin (HA, H1–H18)
and neuraminidase (NA, N1–N11). The virion consists of a seg-
mented negative sense genome encapsidated in ribonucleoprotein
complexes, which are surrounded by a matrix shell and lipid enve-
lope containing the two surface glycoproteins and the M2 ion
channel. Influenza A is the primary source of the human sea-
sonal form of the disease, responsible for up to 500,000 deaths
per annum as well as deaths caused by pandemics such as those
occurring in 1918, 1957, 1968, and 2009 (2). Consequently, vac-
cines against influenza need to be regularly updated to match
predicted circulating strains that are constantly escaping from vac-
cine protection through a mechanism known as antigenic drift.
Influenza A is primarily associated with wild fowl/birds in the
case of the majority of subtypes and can reassort with human
strains through antigenic shift to yield human compatible viruses
with previously un-encountered surface epitopes. Pigs are usu-
ally considered to be the mixing vessel for reassortment as they
express a mixture of α-2,3 and α-2,6 sialic acid linkages. Influenza
virus research is often hindered by the requirement for expensive
biosafety precautions, especially in the case of the highly path-
ogenic avian influenza (HPAI, e.g. H5N1, H7N1) or pandemic
strains.
Pseudotypes or pseudotype particles are chimeric “viruses”
consisting of a surrogate virus core surrounded by a lipid enve-
lope with the surface glycoproteins of another virus, such as HA.
By removing the genetic element of the virus being studied and
replacing it with a suitable reporter, viruses, especially HPAI, can
be studied in this safer, single cycle system. The comparative
safety of pseudotype viruses circumvents the need for restric-
tive, expensive, and widely unavailable high-category biosafety
facilities, increasing access to research groups interested in highly
pathogenic viruses.
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This review is a systematic analysis encompassing a wide range
of peer-reviewed literature in English concerning the produc-
tion and use of pseudotypes bearing influenza glycoproteins to
date. For the purpose of this review, pseudotypes will be defined
as replication-deficient viruses containing a viral core from one
species and bearing glycoproteins from another that are not rep-
resented in the genome. Literature was gathered by searching for
“influenza pseudotypes”using Google Scholar and NCBI PubMed.
The resulting list of publications was expanded by following up
cited references and finally, those falling outside of our pseudo-
type definition or not specifically using influenza pseudotypes
were excluded from the sections on production, transduction, and
neutralization.
This review will be useful to those interested in the produc-
tion of pseudotypes for use in immunogenicity testing of pre-
clinical influenza vaccines, whether in human or animal settings,
and including “universal vaccine” candidates. Influenza serologi-
cal studies such as the measurement of seroprevalence will benefit
from this manuscript, which will also help to inform the process
of validation of pseudotype-based assays to clinical end-point.
Furthermore, studies utilizing chimeric HA proteins in order to
differentiate between stalk and head directed antibodies will be
discussed.
PSEUDOTYPE COMPONENTS
CORES AND REPORTERS
The core and its associated genome containing a reporter are
the backbone of the pseudotype system, which can be used to
study the properties of selected entry proteins. The use of cores
from lentiviral human immunodeficiency virus (HIV) and gam-
maretroviruses such as murine leukemia virus (MLV) predomi-
nate in the influenza pseudotype literature. Recent development of
systems involving rhabdoviruses, in particular the vesicular stom-
atitis virus (VSV), has also been used to produce pseudotype cores
with promising results (3, 4).
RETROVIRAL AND LENTIVIRAL CORES AND VECTORS
Retroviral and lentiviral vectors are complex systems, which will
be explained in simple terms specific to the production and use
of pseudotypes. Pseudotype core and vector systems have been
reviewed in detail (5, 6).
The primary genes provided by retroviral and lentiviral systems
are gag and pol. In the case of HIV, gag provides the structural
proteins p18, p24, and p15, whereas pol provides the integrase and
reverse transcriptase in conjunction with the p10 protease required
for cleavage and maturation of each distinct protein from their
respective polypeptide chain (7, 8). Reporter constructs are asso-
ciated with their respective cores based on the Psi (Ψ) packaging
element incorporated in the vector design process, making them
specific to the surrogate species used.
Human immunodeficiency virus cores are derived from sev-
eral different origins between laboratory groups. First generation
pNL4-3 vectors are well represented and the pNL4-3-Luc.E-R-
variant is the most commonly used (9–14). The pNL4-3.Luc.E-R-
replication deficient proviral HIV-1 clone is derived from the pNL
precursor but has inhibitory frame shifts in the env and vpr genes
as well as a luciferase reporter gene cloned into nef and the entire
construct is incorporated into progeny pseudotypes. The vector’s
life cycle mimics that of HIV, using the Ψ element to allow encap-
sidation into nascent pseudotypes and long terminal repeat (LTR)
regions bearing the U3 promoter, which with the aid of tat, per-
mit the expression of the viral proteins after integration into the
host genome. The rev responsive element (RRE) allows nuclear
export of viral messenger RNA (mRNA), including the reporter
gene transcript, which is the measure of output for this system.
Due to the incorporation of the HIV core genes into the same
integrated construct as the reporter, transduced cells may possi-
bly produce luciferase containing cores alongside its transcribed
enzyme, which could potentially interfere with luciferase activity.
Another commonly used HIV core vector is pCMV ∆R8.2, a
relation of pCMV ∆R8.9, which still contains intact vif, vpr, vpu,
and nef genes (15–20).
A further approach uses the second generation HIV vector
p8.91 that also originates from pCMV ∆R8.9 and ∆R9 (15, 21).
The p8.91 vector is a modified HIV-1 clone, lacking theΨ sequence
as well as the env, vif, nef, vpu, and vpr genes and is widely used
in the articles studied (22–25). The cytomegalovirus promoter is
used in lieu of LTR-based promotion, meaning that p8.91 pro-
vides the necessary genes for the production of the core but the
proviral and packaging elements (LTRs, RRE, and Ψ) are trans-
ferred to a separate plasmid bearing the reporter gene. Thus, the
reporter construct will be incorporated into nascent virions and
integrated into the transduced cell’s genome, whereupon the LTRs
and RRE will act to enhance expression. In the case of the com-
monly used firefly luciferase or green fluorescent protein (GFP)
plasmids pCSFLW or pCSGW, a safety component is incorporated
through a deletion in the 3′ LTR (U3 promoter region), creating
so called self-inactivating (SIN) vectors (26, 27).
Third generation vectors have also been used. In this instance,
HIV structural and accessory genes are separated from rev, which
is provided in cis on an additional plasmid. The third generation
Invitrogen ViraPower Lentiviral Expression System was used in
several cases using the plasmids pLP1 and pLP2 (28–31).
Murine leukemia virus cores are less widely used but provide
similar gag and pol elements to HIV vectors (32–38). One MLV
core used consists of gag and pol under the effect of a CMV pro-
moter, a vector which has been shared across various laboratories
(39–41). In this instance, the vector originates from pCI G3 N, B,
or NB, which are differentially restricted in certain murine cells
based on the mouse resistant gene alleles Fv1N and Fv1B (42). The
reporters used in this system are derived from CLONTECH vec-
tors LNCX and pIRES2-EGFP (39, 41). Another described MLV
plasmid, pkatgagpolATG originates from the ecotropic Moloney
MLV and strain 4070A (17).
Minor differences have been observed when pseudotyping HIV
or MLV cores with influenza glycoproteins (43). Therefore, the
question of which core to use to produce pseudotypes is often
down to choice, preference, and availability (44).
See Figure 1 for schematic representations of packaging
constructs and vectors.
RHABDOVIRUSES
Recombinant VSV viruses are produced expressing GFP in place of
the resident VSV envelope glycoprotein (VSV-G). In certain cases,
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FIGURE 1 | Schematic representation of HIV and MLV derived packaging constructs and vectors.
www.frontiersin.org April 2015 | Volume 6 | Article 161 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carnell et al. Influenza pseudotypes
HA and NA or simply HA are also added to the VSV genome. These
additions produce a replication-competent virus, which will pro-
mote GFP production in infected cells (4). As these recombinant
viruses are not limited to a single cycle of replication, they lack the
safety element found within other systems.
A safer VSV-based alternative involves transfection of surface
protein encoding plasmids (HA/NA) into cells and subsequent
infection with a recombinant VSV. In this way, one can pro-
duce VSV pseudotyped with influenza surface proteins, which lack
entry-glycoproteins in its resident genome, rendering the second
generation of virus infection-incompetent (3).
REPORTER SYSTEMS
The output of the pseudotype system is based on the incorpo-
rated reporter, which mimics the genome of the surrogate virus.
In the case of HIV or MLV surrogates, the reporter will often be
incorporated into the pseudotype in RNA form, which upon trans-
duction will be reverse transcribed, translocated to the nucleus,
and integrated into the host cell genome. The reporter will then be
produced by the host cell and can be used to measure transduction
efficiency.
The primary reporter used in influenza pseudotypes is fire-
fly derived luciferase (45–53). Relative luminescence units (RLU)
or relative luciferase activity (RLA) are used as output, measured
by lysing transduced cells and adding substrate for the luciferase
enzyme, the signal from which is then read using a luminometer.
Green fluorescent protein is also commonly used, in which case
transduction efficiency is determined by counting the number of
fluorescing cells via epifluorescence microscopy or fluorescence-
activated cell sorter (FACS) (54, 55).
Other reporters such as lacZ (29, 54, 56, 57) as well as Gaussia
(58) and Renilla (59, 60) luciferase are also used to a lesser extent.
INFLUENZA ENVELOPE PROTEINS: HEMAGGLUTININ
The trimeric attachment and fusion protein HA is the principal
constituent of the influenza virus envelope, alongside NA and M2.
Attachment to sialic acid residues on target cell membranes trig-
gers endocytosis and pH-dependent exposure and engagement
of the fusion peptide, mediating entry of the virus (61). This
process is the basis on which influenza neutralization assays are
founded – the exploitation of attachment and entry for the study
of HA-directed antibodies and their neutralizing ability. Analysis
has permitted classification of influenza A subtypes into two dis-
tinct groups: group 1 containing subtypes 1, 2, 5, 6, 8, 9, 11, 12, 13,
16, 17, and 18 and group 2 containing 3, 4, 7, 10, 14, and 15 (62–
64). Subtypes within each group are often subdivided into clades
with further sequence dissimilarity.
See Figure 2 for a phylogeny of influenza groups and Figure 3
for influenza strains pseudotyped with HA compared to HA
sequence entries currently in NCBI GenBank. A wide variety of
influenza A strains exist and have been pseudotyped, influenza B
is grouped into two distinct lineages (Yamagata and Victoria) and
has yet to be pseudotyped. Influenza C pseudotypes have been
produced using a VSV core (65).
Codon optimization, synthesized genes
Codon optimization has been employed for several commer-
cially synthesized genes, which are sometimes used concurrently
with extracted wild type viral sequences depending on availability
[Genscript, Gene Art, Integrated DNA technologies (54, 68–73)].
Recursive PCR has been used in some cases to produce the same
end product (16, 68, 74, 75). In the context of pseudotype produc-
tion, codon optimization is performed based on the assumption
that conforming to codon-bias within producer cells will increase
production of proteins and pseudotype yields.
FIGURE 2 | Phylogeny of current influenza subtypes using the HA
glycoprotein. Maximum likelihood tree representing amino acid sequences
of the HA glycoprotein for influenza A, B, and C virus as well as putative
influenza D. The tree inferred is based on MUSCLE alignment of downloaded
sequences conducted using MEGA 5.2 under the WAG+G model (four
categories). The phylogenetic tree with the highest log likelihood
(−16773.4044) is shown. The tree is drawn to scale, with branch lengths
measured in the number of substitutions per site. The analysis involved 22
amino acid sequences. All positions containing gaps and missing data were
eliminated. There were a total of 538 positions in the final dataset (66, 67).
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FIGURE 3 | Comparison of influenza HA sequences described against
strains pseudotyped. Out of a total of 60,693 HA amino acid sequences
extracted from NCBI GenBank, the vast majority come from subtypes H1,
H3, H5, and influenza B. Conversely, the current number of different
subtypes and strains of HA used to produce pseudotypes is 82.The majority
of pseudotyped strains come from subtypes H1, H3, and especially H5.
INFLUENZA ENVELOPE PROTEINS: NEURAMINIDASE
As with wild type influenza virus, NA is required for the exit
of influenza pseudotypes via its cleavage of surface sialic acid
molecules on producer cells. However, it is common to circum-
vent the requirement of NA expression for pseudotype produc-
tion by the treatment of cultured cell lines with commercial
exogenous bacterial NA 24 h after transfection (59, 76–78). This
24 h time period requires optimization to allow maximal bud-
ding of pseudotypes and minimal loss through transduction of
producing cells. Exogenous NA treatment is often used in neu-
tralization studies in order to prevent NA directed antibodies
from providing a neutralization signal. However, several studies
opt to incorporate an NA plasmid such as that from influenza
B/Yamagata/16/88, A/Shanghai/37T/2009, A/Thailand/1(KAN)-
1/04, or A/Puerto Rico/8/1934 (16, 58, 79–85).
Several recent articles have characterized sialic acid binding
attributes of neuraminidases sharing particular genetic character-
istics. New mutations have been characterized such as G147R in
the A/WSN/33 strain that has been shown to rescue HA-binding
deficient viruses. The G147R mutation is present in a range of
strains including representatives of pandemic H1N1 and chicken
H5N1 (86, 87).
INFLUENZA ENVELOPE PROTEINS: M2
It is also possible to incorporate the M2 ion channel into influenza
pseudotypes in order to study its effect on the production process.
However, the M2 role in acidification of the wild type influenza
virus core is not required for the dissociation of pseudotype cores
as they are derived from non-influenza viruses, which achieve
release of their genetic material (i.e., a luciferase reporter gene
transcript) through different mechanisms. Therefore, M2 is not
required for the production of influenza pseudotypes despite being
shown to have an effect on yields and infectivity (88, 89). There are
reports of M2 incorporation increasing pseudotype particle yields
such as H7 A/FPV/Rostock, and for H1N1 pseudotypes (29, 88).
M2 has been shown to influence the budding of wild type influenza
and consequently, this may be the mechanism through which M2
expression increases the reported pseudotype yields (90).
PROTEASES
As HA is produced and trafficked through the secretory pathway it
requires proteolytic cleavage in order to become fusion competent.
Proteolytic cleavage is mediated by certain host cell proteases and
restricts certain subtypes to epithelial cells where these required
proteases are expressed. While this is achieved naturally in wild
type infection, a cleavage component must be incorporated into
pseudotype production workflows in order to achieve optimal
yields. This is because in producer cell lines the required proteases
are either not expressed or are expressed, but not at sufficient levels
to make the pseudotypes fusion competent.
In order to mimic the proteolytic properties of the natural host
cells of influenza, protease encoding plasmids can be transfected
alongside the other requisite plasmids in order to induce tran-
sient expression within the same timeframe as the production
of pseudotypes. The serine transmembrane protease (TMPRSS2)
and the human airway trypsin (HAT), which cleave wild type
influenza (91) have been used successfully in several studies for
pseudotype production (17, 28, 70, 78, 92–96). TMPRSS4, another
serine protease has also been used to successfully cleave wild type
and influenza lentiviral pseudotypes (97).
However, the addition of a protease encoding plasmid can be
side-stepped through cleavage post-production using tosyl pheny-
lalanyl chloromethyl ketone (TPCK) treated trypsin (17, 28, 92,
98). TPCK inhibits the less specific proteolytic elements of chy-
motrypsin, restricting the treatment process to the cleavage of
peptide bonds required for HA maturation (99, 100).
TPCK-trypsin concentrations used for the production of
pseudotypes generally ranged from 1 to 50µg/ml. However, one
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FIGURE 4 | Production of lentiviral or retroviral pseudotypes.
(A) Essential (containing HA, packaging construct gag pol, reporter
construct) and/or additional (NA, protease, M2) expression plasmids are
co-transfected into HEK293T producer cells. (B) Plasmids migrate to the
nucleus whereupon genes are expressed leading to the production of
pseudotype proteins and the reporter RNA construct. Cleavage of HA is
mediated by transfected or cellular proteases. (C) Pseudotype proteins
are packaged by the cell and budding occurs at the cell membrane to
yield pseudotypes bearing desired glycoproteins and incorporated
reporter.
study reported increased transduction when used at concentra-
tions above 40µg/ml for H1N1 pseudotypes (101). Incubation
ranged from 10 min at room temperature to the more usual
1 h at 37°C. TPCK-trypsin treatment is typically carried out an
hour before transduction. The enzyme is then neutralized before
transduction using commercial trypsin inhibitors, in some cases
originating from soybean (28, 92).
HA derived from HPAI strains that contain a polybasic
cleavage sequence in the HA0 protein are cleaved by a wider
range of proteases that are ubiquitous in cells. This allows the
omission of protease plasmids or TPCK-trypsin treatment in
HPAI pseudotype production (102). In some cases, the poly-
basic cleavage site of HPAI strains have been integrated into
other HAs in an attempt to produce pseudotypes without the
protease plasmid requirement, or to give strains similar entry
characteristics (60, 73).
See Figures 4 and 5 for representative drawings of the
pseudotype production process and different cores used.
PRODUCTION METHODS
PLASMIDS RATIOS AND AMOUNTS
There is considerable variation between studies regarding choice
of expression plasmids as particular systems are established within
research groups and networks, inherited from previous studies and
are often dependent on collaborations or gifts. The most popu-
lar system employed involves a multiple plasmid co-transfection
approach using separate plasmids for the HA, reporter and retro-
viral gag and pol core genes. These genes are cloned into a range
of expression plasmids such as pI.18, pcDNA3.1, phCMV, and
pCAGGS (43, 74, 103, 104). Kozak consensus sequences are very
rarely mentioned and only defined in one study, in which a
FIGURE 5 | Pseudotype cores. (A) HIV cores with various envelope
glycoproteins (HA, NA, M2). (B) MLV cores with HA or HA and NA.
(C) Recombinant VSV containing GFP gene (top) and HA/NA/GFP genes
(bottom). Components of influenza pseudotypes can be varied according to
need. Pseudotypes have been produced with HA, NA, and M2 influenza
envelope proteins, with a range of core packaging constructs (HIV, MLV,
VSV shown) as well as different reporters.
kozak consensus sequence derived from the pHW2000-N1 (Kan)
plasmid was used (3).
Additional plasmids encoding NA and M2 are sometimes used
when studying the relevant aspects of influenza infection or
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pseudotype production, but more rarely in the case of neutraliza-
tion (93, 105). In one study, a 10- to 30-fold increase in pseudotype
production was achieved through expression of M2 using lentivi-
ral cores and a 5-fold increase was achieved when an MLV core
was used (29).
Plasmid ratios are crucial to pseudotype production but spe-
cific to plasmids used as well as transfection methods. In order to
attain the highest quality and yields, optimization is required. Typ-
ically, the“core:HA:reporter” plasmid ratio is 1:1:1.5. However, the
“HA:NA” ratio ranges from 3:1 to 8:1 and protease gene bearing
plasmids (HAT, TMPRSS2) are often present at 50% (or below)
the concentration of HA (e.g., 1µg HA plasmid to 0.5 or 0.25µg
protease plasmid). Calcium phosphate precipitation requires the
highest plasmid input, with as much as 25µg of each plasmid per
100 mm dish used, whereas other methods [Fugene, polyethylen-
imine (PEI), Lipofectamine] require quantities of between 1 and
5µg for each plasmid per 100 mm dish (20, 29, 69). Plasmid ratios
are differentially affected by the composition of plasmids and
therefore the quantities used to produce pseudotypes in the liter-
ature are justified based on optimization carried out by particular
laboratories (17, 72, 88).
PRODUCER CELLS
The producer cell lines used for pseudotype production are pre-
dominantly Human Embryonic Kidney 293 cells transformed
with the SV40 large T antigen (HEK293T, 293T). These cells are
highly susceptible to transfection and make good retroviral pack-
aging cells (106). The clone 17 (HEK293T/17) of this cell line is
also extensively used to produce high-titer influenza pseudotypes.
Other cell lines used include 293FT cells (Invitrogen) used in the
production of VSV–HA–NA pseudotypes (3).
Where mentioned, cell confluency at transfection varies
between 60 and 90% with cells subcultured 24 h before trans-
fection (74). Cell monolayers are grown on dishes ranging from
60 to 150 mm with the occasional study using T75 Flasks or
multi-well plates (74, 107). Transfections are usually carried out
using medium with serum such as fetal bovine serum (FBS) at
concentrations of up to 10% (83, 108, 109).
TRANSFECTION REAGENT/METHOD
The methods studied use the following chemical transfection
reagents: Lipofectamine, Lipofectamine 2000 (Thermo Fisher Sci-
entific), Fugene-6, Fugene-HD (Promega), PEI, jetPEI (Polyplus
Transfection), or calcium phosphate precipitation. The choice
of reagent is based on optimized lab protocol, cost, as well as
the cytotoxicity of each reagent depending on requirements of
pseudotype production. Of the above reagents, calcium phosphate
precipitation and Fugene-6 are the most popular.
Calcium phosphate precipitation is a well-established transfec-
tion method of mammalian cells, developed in 1973 by Graham
and van der Eb. This method involves mixing a comparatively
high amount (5–25µg) of plasmid DNA with calcium chloride
and then adding this mixture slowly to a buffered saline solution.
The mixture is incubated at room temperature whereupon a posi-
tively charged DNA and calcium phosphate precipitate is formed.
The charge allows the precipitate to associate with the negatively
charged cell membrane, entering by endocytosis or phagocytosis.
The calcium phosphate precipitation process is sensitive to small
differences in pH (20, 110, 111).
Polyethylenimine is a polymeric cation, which was first evalu-
ated for its transfection capabilities in 1995. PEI acts at a range of
pH values and associates with DNA to produce a complex with an
overall positive charge that can then allow interaction with the cell
membrane. Entry is by endocytosis and PEI has been shown to aid
the delivery of nucleic acids to the cell nucleus of transfected cells.
The original report states that PEI is non-cytotoxic at optimal
concentration for transfection (112). However, when using PEI
for transfection, it is commonplace to change cell culture medium
within 24 h of transfection. JetPEI is a manufactured linear form
of PEI, which is suited to high-throughput assays (84, 113).
Lipofectamine (or Lipofectamine 2000) are cationic lipids sold
by Invitrogen that allow delivery of nucleic acids such as vec-
tors into host cells through the formation of positively charged
liposomes. The liposomes containing the pseudotype vectors are
then able to fuse with cell membranes due to their positive charge
and lipid constitution (114). Lipofectamine is among the most
expensive transfection reagents used in influenza pseudotype pro-
duction. The benefits of using this method are not readily apparent
when the cost of the reagent is considered (107, 115).
Fugene-6 and Fugene-HD are cationic lipid complexes, which
have low cell cytotoxicity. This allows laboratories to avoid replac-
ing the transfection medium that may allow an increase in
final titers of pseudotype when harvested. Fugene-HD has been
shown to be more efficient than other transfection reagents
(17, 96, 116, 117).
Table 1 shows a list of transfection reagents, their cytotoxicity,
cost, and plasmid input required.
CELL WASHES AND MEDIUM REPLENISHMENT
In transfections where cytotoxic reagents are used, medium is
replenished 6–24 h post-transfection, with most studies stating
that media is typically replenished after overnight incubation (73).
Media replacement can also be accompanied by a PBS wash. Where
rhabdoviruses are used for pseudotyping, cell lines are washed
using PBS 12 h after transfection with influenza surface glycopro-
tein plasmids. Helper virus is then added and 4 h later the helper
virus containing medium is replaced after a further PBS wash
step (3).
SODIUM BUTYRATE
Sodium butyrate, a compound that can increase cell proliferation
and pseudotype production is used in several studies with the
concentrations ranging from 10µM to 10 mM (18, 28, 57, 68).
Table 1 |Transfection reagents, price, cytotoxicity, and plasmid input.
Transfection reagent Price Cytotoxicity Plasmid input
Lipofectamine 2000 High – Low
Fugene-6 High Low Low
Fugene-HD High Low Low
Polyethylenimine (PEI) Low Low Low
Jet PEI Medium High Low
Calcium phosphate precipitation Low – High
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HARVEST
Pseudotypes are harvested at various time intervals, typically 48 h
post-transfection but sometimes also at 24 or 72 h. The super-
natant is taken from the transfected cell monolayer and passed
through a 0.45µM filter to remove cell debris before being stored
at −80°C. In many cases, centrifugation at low or high speed is
used to concentrate harvested virus (20, 29, 57, 68, 77, 89, 105,
115, 118, 119).
One study has demonstrated that influenza pseudotypes are
stable after five freeze–thaw cycles, retaining over 80% infectiv-
ity. Keeping pseudotype supernatant at −20°C for 6 months had
a similar effect. However, storage at−4 or 20°C led to a reduction
in infectivity of 50% in both cases (120). In environments lack-
ing reliable refrigeration facilities, pseudotypes can be lyophilized
and stored at a range of increased temperatures and humid-
ity, maintaining viability and concentrations adequate for use in
neutralization assays (121).
See Figure 6 for a detailed depiction of methods used for pro-
duction based on all pseudotype employing articles cited in this
review.
TRANSDUCTION
TITRATION
As previously mentioned, with luciferase reporter pseudotypes
RLU readings derived from titrations can be used as a secondary
measure of pseudotype concentration within a sample. However,
RLU readings are dependent on many variables surrounding the
cells and the particular luminometer used.
Pseudotypes are titrated by 2-fold serially diluting 100µl of
harvested supernatant in a 96-well plate. After an incubation of 48
or 72 h, RLU can be measured by lysing the transduced cells and
adding luciferin (luciferase substrate). This can then be used to
calculate the RLU per well and the RLU/ml of the original sample.
Reverse transcriptase quantitative PCR (qRT-PCR) has also
been employed in order to estimate transfected gene copies as well
as mRNA copies in cells. This method is often used in conjunction
with others described in this section in order to have comparative
measurements of pseudotype quantity (55, 109, 122).
In many studies, pseudotype input is normalized via enzyme-
linked immunosorbent assay (ELISA) detection of the principal
component of the HIV core, p24 (16, 17, 28, 54, 59, 88, 89, 92, 95,
103, 109, 113, 115, 123, 124). However, as core budding is indepen-
dent of surface HA, this method will detect cores lacking envelope
glycoproteins as well as cores belonging to transduction competent
pseudotypes. Pseudotype HA has also been detected using ELISA
and used to normalize pseudotype input (82, 98, 125).
Quantification through hemagglutination assay has also been
used frequently (28, 55, 58, 82, 84, 95, 98, 101, 122, 126–128).
Western blotting is used in some cases to determine the amount
of glycoprotein or HIV p24 in a pseudotype sample (59, 72, 109).
It is also used in a wider range of studies to ascertain glycoprotein
or HIV p24 expression (17, 28, 55, 109, 122).
CELL INPUT
The vast majority of studies involving neutralization assays titrate
and transduce in 96-well plates with 1× 104 cells (HEK293,
HEK293T/17, or MDCK) per well. However, the amount of cells
can range from 5× 103 to 1× 105. In some instances, 293A and
MDCK-London cells are also used, whereas BHK-21 cells are fre-
quently used for VSV-based pseudotype infection due to their
comparative susceptibility (65, 73, 93, 95, 129–132). Specialized
cells overexpressing α2,6-linked sialic acid (MDCK-SIAT) have
also been used and compared to parental cells in the presence of
soluble HA (77).
In one case, transduction was carried out in 96-well transpar-
ent culture plates, before lysates were then transferred to 96-well
luminometer plates for analysis (69). The importance of pseudo-
type input in batch to batch variation is highlighted in Garcia et al.
(133), the study suggests that an RLU of at least 1× 105 per well
should be used to ensure that antibody titer is independent of
pseudotype input.
SUBSTRATES
Steady-Glo or Bright-Glo (Promega) are the most common
sources of luciferin. While expensive, these two substrates also
serve a secondary purpose of lysing cells and releasing any
expressed luciferase enzyme.
EQUIPMENT: 96-WELL PLATES AND LUMINOMETERS
There is some disparity in the recording of equipment used in
the articles studied for this review. Without this required informa-
tion, reproduction of each study is hampered by these further
variables relating to plate reading. Information relating to the
color and manufacturer of 96-well plates is very important in the
quantification of viable pseudotypes in order to prevent introduc-
tion of further variables between laboratories. While logistically
difficult, the standardization of neutralization assay equipment
across laboratories studying influenza would bring benefits to the
interpretation of research data. Standardization of plate reading
equipment is also required in order to ensure comparable data
are obtained from different machines when reading the same
experiment.
HIGH-THROUGHPUT APPROACHES
A high-throughput approach has been used to evaluate antivi-
ral compound effects on pseudotype transduction, testing a wide
range of unique compounds in a single assay performed with 96-
or 384-well plates (115, 134).
INCREASED TRANSDUCTION EFFICIENCY
Polybrene (hexamethrine bromide) and polyfect (Qiagen) are used
in several studies in order to increase transduction efficiency (17,
29, 58, 68, 76, 79, 80, 98, 135). 1µg/ml, 8µg/ml, or 16 mg/ml of
polybrene is added to virus or virus/antibody mixes before the
addition of cells in titration and neutralization assays or during
incubation.
In two studies, spinoculation was used to increase transduction
rate. To achieve the increased transduction rates, the pseudotypes
and cells were centrifuged at 1250 rpm for 2 h or 3000 rpm for
1 h (3, 92).
PSEUDOTYPE NEUTRALIZATION ASSAYS
PROTOCOL
Pseudotype neutralization assays (pMN) are usually carried out in
96-well white plates. A measured amount of antibody in medium is
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FIGURE 6 | Pseudotype production methods. Graphical representation
of the methods used for pseudotype production in the literature cited in
this review. (A) Method of HA cleavage used. (B) Method of NA action
used. (C) Pseudotype cores used. (D) Reporters incorporated into
pseudotypes. (E) Transfection reagents for the production of
pseudotypes.
serially diluted across the plate and incubated with a set amount of
quantified virus in medium, usually at a 1:1 virus:antibody ratio.
Incubation is carried out at between 20 and 37°C for between
30 min to 2 h (43, 82, 96, 123, 133, 136). About 1× 104 target cells
are then added to each well, subsequently the plate is left to incu-
bate at 37°C in 5% CO2 for 48 or 72 h. A cell-only control as well
as known positive and negative sera standards should be used as
benchmarks for the neutralization assay (95, 113). See Figure 7 for
a depiction of the pMN assay.
PSEUDOTYPE INPUT
The quantities of pseudotype used in neutralization assays, which
were normalized based on p24 ELISA ranged from 6.25 to 50 ng/ml
(17, 95). RLU or RLA values of between 1× 104 and 1× 106 per
well were used (in a 96-well plate), sometimes in conjunction or
normalized with p24 or qPCR methods (89, 121, 127). Estimates
of copy number per set volume of original viral supernatant can
also be used. It is important to note that RLU based values are
affected by the make-up of the plasmid bearing the HA gene, as
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FIGURE 7 | Example of a pseudotype neutralization assay (pMN).
Serum or antibodies are serially diluted across a 96-well plate, a known
quantity of pseudotype is added and the plate is centrifuged and incubated
to allow antibody binding. A set quantity of cells are added and plates are
incubated for 48 h. Output is measured in a manner depending on reporter
used.
well as a multitude of factors such as the luminometer, which is
used to measure transduction.
SERUM/ANTIBODY DILUTIONS AND START POINTS
Antibody input varies depending on availability, especially when
taking into account the possibility of repeats and replicates.
Antibodies are primarily diluted 2-fold in Dulbecco’s modified
eagle medium (DMEM), with or without FBS, across a 96-well
plate, with the occasional three, four, or 5-fold dilution experi-
ment (3, 18, 58, 137, 138). Where mentioned, starting antibody
concentration ranged between 1:4 and 1:40.
INCUBATION TIMES AND TIME PERIODS
When stated, serum complement inactivation varies from 30 min
to 1 h at 56°C (68, 133). Pseudotype-antibody incubation times
are generally consistent between studies, at 37°C for 1 h. Trans-
duction times vary in 24 h increments at 24, 48, and 72 h, after
which output is measured.
CONTROLS
Positive sera or specific commercial antibodies are required as pos-
itive controls, which can be compared to tested sera and used to
normalize between assays (see Approaches Toward Validation and
Standardization). Reference sera from the National Institute for
Biological Standards and Control (NIBSC), Office International
des Epizooties (OIE), Animal and Plant Health Agency (APHA,
previously AHVLA), and US Food and Drug Administration
(FDA) are regularly used (88, 89, 127, 139, 140).
NEUTRALIZING ANTIBODY TITER DETERMINATION
Antibody effect is displayed using one of many inhibitory concen-
trations (IC50, IC80, IC90, and IC95). The numerical value relates
to the percentage point each particular study is calculating. For
example, the IC50 value can represent the concentration of an
antibody that reduces RLU reading by 50%, when compared to
100 and 0% transduction controls (48, 68, 141, 142). These con-
trols are essential to the calculation. About 100% inhibition can
be benchmarked by a cell-only control and 0% by incubation of
cells and virus in the absence of sera.
HEMAGGLUTINATION-INHIBITION ASSAY
Hemagglutination-inhibition assay (HI) assays using pseudotypes
utilize the same procedures as with wild type virus. A quanti-
fied amount of viral sample (as determined by hemagglutination
assay) in phosphate buffered saline is added to serially diluted sera
in a 96-well plate, to which 50µl of a 0.5–1% chicken/turkey red
blood cell suspension is added. After 30 min to 1 h, the HI plates
are scored for agglutination. Pseudotype input is adjusted accord-
ing to WHO guidelines at four hemagglutination units and sera is
treated with receptor destroying enzyme to inactivate non-specific
inhibition of agglutination (37, 98).
POST-ATTACHMENT ASSAY
The post-attachment neutralization assay is used to identify anti-
bodies that neutralize HA after it has bound to sialic acid. Oh et al.
(143) modified the post-attachment assays, originally developed
by Edwards and Dimmock (144), to allow wild type influenza virus
to be replaced by influenza pseudotype particles.
In this assay, pseudotype particles are incubated at 4°C with
cells to enable the synchronization of the attachment of virus to
sialic acid on the cell surface and to block viral endocytosis. A
diluted serum is then added, and following another 4°C incuba-
tion, plates are transferred to 37°C to permit transduction (143).
Transduction is then measured using the same approach as that
taken in a neutralization assay.
Antibodies detected by this assay have neutralizing activity
via their ability to impede the endocytosis step and subsequent
HA conformational changes necessary for virus–endosome fusion
(143, 144). Antibodies that have neutralizing activity through
impeding viral attachment will produce negative results in this
assay. The post-attachment assay is useful for evaluating the neu-
tralizing capacity of stalk-directed antibodies that do not inhibit
viral attachment (143, 145).
CROSS REACTIVITY
The issue of cross-reactive sera has been raised previously in tradi-
tional serological assays, serum samples produced by injection of
wild-type virus into mice have been shown to lead to the presence
of interfering antibodies directed toward NA or M2 epitopes (146,
147). It is expected that pMN will suffer from the same problems
of cross-reactivity, an important issue, which must be addressed
in the future in order to strengthen the usefulness of this assay as
a competitor to the current gold standards.
REPRODUCIBILITY
Reproducibility is a major issue in the field of serology. Serum
samples are often finite, leading to an inability to reproduce
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experiments or results in the same context as they were originally
published. However, by standardizing methods for production,
titration, and neutralization and the use of common reference
standards it is possible to minimize variation between experiments
and research groups.
CORRELATION WITH OTHER SEROLOGICAL ASSAYS
Comparisons have been made between pMN assays and tradi-
tional serological assays with mixed results. Several articles report
increases of between 31.9 and 200% in human antibody titers in
comparison to microneutralization (MN) based results (148, 149).
Buchy et al. (148) show a correlation between H5 pseudotypes and
MN (spearman 0.79, p< 0.001), which is also seen in Du et al. (69)
and Wang et al. (89), the latter presenting r2 values of 0.9802 for
A/Vietnam/1203/2004, 0.8193 for A/Anhui/1/2005, and 0.5244 for
A/turkey/Turkey/1/2005 strains.
Alberini et al. (137) compared pMN assays to hemagglutination-
inhibition (HI), single radial hemolysis (SRH), and MN assays
using 226 different human serum samples. The Pearson correla-
tion test produced significant correlation (p< 0.001) between the
antibody titers calculated from each assay. The correlation coeffi-
cients between pMN and HI, SRH, and MN assays were 0.73, 0.70,
and 0.78, respectively. Furthermore, the correlation between H5
MN and H5 pMN allowed the establishment of a threshold from
which pMN titers could be based. pMN data were then analyzed
based on the threshold, which showed protective titers in patients
of 38–43, 54, and 79% after adjuvanted vaccination, second dose
and booster, respectively (137).
Qiu et al. (81) show a range of correlations between HI and
pMN using different HA subtypes. A/Moscow/10/1999 (H3N2)
correlates well (r = 0.8454, p< 0.0001), A/Brisbane/59/2007
(H1N1), and A/Japan/305/57 (H2N2) poorly (r = 0.1171, p=
0.7472 and r = 0.1171, p= 7472) whereas A/Vietnam/1203/2004
(H5N1) correlates (r = 0.7921, p= 0.0029). In an additional study,
HI and pMN (IC50) correlate well in Qiu et al. (107) in the case of
A/Shanghai/4664T/2013 (H7N9) (spearman r = 0.88, p< 0.0001)
as well as in Whittle et al. (126) (r2= 0.6491, p< 0.0001).
A significant correlation of 65% (p= 0.002, r = 0.65) has also
been reported between SRH and pMN using equine influenza
pseudotypes and sera and another study showed the relationship
between RLU and HA content (78, 119).
APPROACHES TOWARD VALIDATION AND
STANDARDIZATION
Approaches toward the standardization of pMN should follow the
procedure that was required for MN standardization. Standard-
ization of MN in general has focused on the use of pooled serum
samples as reference standards. A/California/7/2009 (pandemic
H1N1, pdm) standard was established by the WHO in 2010 with
an assignment of potency of 13,000 IU/ml. A second pooled sera
reference standard for H5N1 exists and has successfully been used
in a number of studies (89, 137, 150). A cut off value for positive
and negative H5N1 neutralizing sera exists for this set of H5N1
reference standards (137).
CHIMERIC HEMAGGLUTININ AND STALK-DIRECTED
ANTIBODIES
There has been considerable research into the stalk region of HA
in relation to vaccine design and immunity to influenza. Various
stalk-directed monoclonal antibodies (mAB) such as CR6261 have
been characterized, opening up the potential use of chimeric HA
to test for the presence of similar antibodies in serum samples
(151, 152).
Stalk-directed antibodies were first identified in 1994 when the
cross-reactive C179 mouse monoclonal antibody was identified
and found to inhibit fusion of several HA subtypes (153). Since
then many studies have focused on stalk-directed antibodies and
their neutralization of multiple diverse subtypes of influenza (145,
152, 154–156). However, this range of heterosubtypic immunity is
dependent on the characteristics of the epitope of each antibody
tested, which will influence which subtypes, clades and whether
they neutralize group 1 or 2 influenza.
The stalk region of HA is more conserved than the variable
globular head to which the vast majority of neutralizing antibod-
ies are directed. While residues in the head mediate attachment
of the virus to target cells by binding to sialic acid, the fusion
peptide in the stalk of HA is just as crucial to the HA function
(157, 158). In order to test for neutralizing stalk antibodies, stud-
ies have employed a variety of chimeric HA constructs bearing
stalks and heads from different subtypes. The concept behind this
revolves around the use of HA heads that are largely unreactive
to the antibodies used in the assay. Utilizing this approach, a neu-
tralizing response can be detected in the absence of head-directed
neutralization.
Several hybrids have been constructed and pseudotyped using
HIV cores, these are generally constructed through PCR ampli-
fication and incorporation of complementary restriction sites,
allowing ligation of different segments of HA genes. A wider
variety has been used in reverse genetics approaches toward devel-
opment of wild type virus bearing chimeric HAs (159–161). These
chimeric HA are promising candidates for the testing of “universal”
vaccines.
Table 2 displays the regions and subtypes used in the construc-
tion of chimeric hemagglutinins. Figure 8 is a visualization of
chimeric HA construction in the form of a computer model.
FUTURE OF INFLUENZA PSEUDOTYPES
Pseudotype neutralization assay offers the safety of using pseudo-
types and the sensitivity of the MN assay. Further validation
Table 2 | Examples of chimeric hemagglutinins originating from
divergent subtypes and used for pseudotype production.
Reference Head Stalk
Hai et al.
(58)
H5 A/Vietnam/1203/2004 H1 A/Puerto Rico/8/1934
H1 A/California/04/2009 H1 A/Puerto Rico/8/1934
H7 A/mallard/Alberta/24/2001 H3 A/Perth/16/2009
H5 A/Vietnam/1203/2004 H3 A/Perth/16/2009
Pica et al.
(80)
H6 A/mallard/Sweden/86/2002 H1 A/Puerto Rico/8/1934
H9 A/guinea fowl/Hong Kong/
WF10/1999
H1 A/Puerto Rico/8/1934
HA1 HA2
Wang
et al. (72)
A/Brisbane/59/2007 A/New Caledonia/20/1999
A/New Caledonia/20/1999 A/Brisbane/59/2007
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FIGURE 8 | Computer models of chimeric HA. Three-dimensional
structures were generated with Swiss PDB viewer and POV-Ray 3.7 using
the structure of the recombinant virus A/Hong Kong/1/1968 X-31 H3 [PDB
ID: 2VIU (162)]. The signal peptide is not present in the HA. The
transmembrane region is not resolved by X-ray crystallography.
(A) Three-dimensional structure of the influenza HA trimer, showing the HA
surface of the head (blue) and stalk (red) regions. (B) Three-dimensional
ribbon structure of the influenza HA monomer showing the head (blue) and
stalk (red) regions. (C) Three-dimensional ribbon structure of the influenza
HA monomer showing HA1 (blue) and HA2 (light blue) subunits, the
cleavage site and the fusion peptide are also shown in green and red,
respectively. (D) Schematic of the HA polypeptide.
and standardization of the assay are required but once estab-
lished, the assay should offer a robust and sensitive means of
interrogating influenza vaccine trials for head and stalk-targeting
antibodies. The production of vaccines that elicit stalk-targeting
antibodies may in time lead to a universal vaccine, preventing
250,000–500,000 deaths from seasonal influenza and the emer-
gence of pandemic strains, most recently the H1N1 2009 pdm,
which caused an estimated 284,500 deaths (163). pMN currently
offers the opportunity to batch test vaccines or commercialized
antibodies in the absence of standardization.
Furthermore, the ability of the pMN assay to include chimeric
HA, and also NA and M2 allows the pMN to be used to explain
the pathogenicity of seasonal and pandemic influenza strains and
perhaps elucidate the antigenic evolution of influenza further.
OTHER USES OF PSEUDOTYPING INFLUENZA
GENE THERAPY AND VACCINES
As the field of gene therapy progresses, influenza pseudotyping will
benefit from the design of even safer and more effective vectors. As
more sophisticated systems are developed they may become more
easily standardized and comparable to wild type virus.
One aspect of gene therapy that may benefit the field of
influenza is the use of viral entry proteins to target delivery of
nucleic acids into specific cells, as vaccines or delivery systems. One
delivery system study used influenza pseudotypes to transduce the
respiratory epithelial cells of mice after nasal administration with
promising results indicating that the method could be used in the
treatment of cystic fibrosis (118). A similar study presented the
rescue of ciliary function using influenza pseudotypes containing
therapeutic cDNA (164).
Pseudotype-based influenza gene delivery vaccines are also
becoming more widespread, with several candidates already cited
in this review. Baculovirus pseudotyped with VSV-G has been used
successfully to express HA in mammalian cells and provided an
efficacious vaccine when tested in chickens and mice (165). Orig-
inally a popular vector for transgene expression in insect cells,
baculovirus has been shown to be a useful tool for vaccine pro-
duction in mammalian cells (166). In Wu et al. (165), delivery was
achieved through VSV-G incorporation into baculovirus under
the effect of the polyhedron promoter and HA under the effect of
the CMV promoter in order to achieve expression and subsequent
infection of mammalian cells. This is an interesting gene delivery
system, which could be used as a method for the introduction of
pseudotype genes into cells through a VSV-G bearing baculovirus
in lieu of cytotoxic transfection reagents.
A further pseudotype vaccine has been developed which con-
tains a modified HA gene, allowing expression in transduced cells
but lacking the viral RNA sequences required for replication. This
approach yields a particle bearing the desired glycoproteins, in
this case A/Puerto Rico/8/1934 (H1) that consequently induces a
robust T-cell response when given to mice via inhalation. Reduc-
tion in the severity of symptoms was also seen in mice infected with
a different subtype: H3N2, A-X31 (71). While these approaches
demonstrate the flexibility of the pseudotype platform, other more
established methods including adenovirus or modified vaccinia
viruses (e.g., modified vaccinia Ankara) may present a more attrac-
tive option for the delivery of influenza genes, and have been
reviewed in great depth (167).
Pseudotypes used as immunogens, such as those bearing H5
have been tested in mice as a candidate vaccine, eliciting high levels
of anti-HA antibodies as determined by HI. Mice that were vac-
cinated survived despite weight loss of approximately 12.8–21.1%
whereas the non-vaccinated group lost approximately 25.5–26.2%
of their bodyweight and perished 6 days after H5N1 virus chal-
lenge (20). A similar approach is taken by Szécsi et al. (168) in
the production of H5 and H7 pseudotyped virus-like particles as
immunogens tested in mice.
Influenza pseudotypes could also be used in vaccine design
through the use of integrase defective lentiviral vector technology.
Defective lentiviral vector technology allows transduction of tar-
get cells through maintenance of an episomal reporter construct
without integration into the genome. This approach may bring
benefits by reducing the chance of interrupting host genes and the
eventual dilution of the delivered gene over time (169, 170).
See Figure 9 for a depiction of the various pseudotype-based
vaccines and immunogens.
RECOMMENDED CONSENSUS PROTOCOL FROM SYNTHESIS
OF PUBLISHED ARTICLES
PRODUCTION PROTOCOL
A HEK293T cell monolayer of 60–90% confluence should be
transfected using Fugene-6 or calcium phosphate precipitation
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FIGURE 9 | Pseudotypes used for gene delivery or as immunogens.
Pseudotypes can be employed as immunogens bearing the antigen of
choice or as delivery systems for genes of choice. (A) HA-based
pseudotype/virus-like particle immunogen. (B) VSV-G pseudotype delivery
system for HA gene. (C) HA pseudotype delivery system for HA gene.
in medium containing 10% FBS. Plasmid ratios should be opti-
mized based on the plasmids used. The use of second generation
HIV packaging constructs is recommended. An NA encoding
plasmid can be used or exogenous NA can be added at 24 h post-
transfection to induce release of pseudotypes. The supernatant
should be harvested at 48 h post-transfection and filtered through
a 0.45µm filter. Filtered supernatant should be kept at −80°C in
single use aliquots if long-term storage is required.
TITRATION PROTOCOL
Titration should be carried out using luciferase-based transduc-
tion in 96-well white plates, by p24 ELISA or other methods
of quantification. Quantification of pseudotype particles using
luciferase-based transduction involves the 2-fold serial dilution of
100µl of pseudotype in 10% FBS medium. About 1× 104 cells
are then added in a 50µl volume and the resulting solution is
incubated for 48 h. After the 48-h incubation period luciferase
substrate is added to each well and RLU values are read. Cell only,
∆Env and VSV-G bearing pseudotypes can be used as negative
and positive controls.
PSEUDOTYPE-BASED NEUTRALIZATION PROTOCOL
Serum samples are serially diluted across a 96-well plate in 50µl
of media. Pseudotype virus should be added in a 50µl volume
at a concentration of 1× 106 RLU. After 1 h incubation at 37°C,
1× 104 HEK293T or MDCK cells should be added in a 50µl vol-
ume. The plate is then incubated at 37°C for 48 h before luciferase
substrate is added to each well, after which RLU values are read.
Standards should ideally be used in the form of neutralizing
antibodies or pooled serum samples.
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